FMP

FMP

Enter

AGIO - Agios Pharmaceuticals, Inc.

Profile of Agios Pharmaceuticals, Inc.(AGIO), Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development o

photo-url-https://financialmodelingprep.com/image-stock/AGIO.png

Agios Pharmaceuticals, Inc.

AGIO

NASDAQ

29.24 USD

0.12 (0.41%)

About

ceo

Mr. Brian M. Goff M.B.A.

sector

Healthcare

industry

Biotechnology

website

https://www.agios.com

exchange

NASDAQ

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CIK

0001439222

ISIN

US00847X1046

CUSIP

00847X104

Address

88 Sidney Street

Phone

617 649 8600

Country

US

Employee

389

IPO Date

Jul 24, 2013

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep